Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The therapeutic time window--theoretical and practical considerations.

C Y Hsu1, S H Ahmed, K R Lees

  • 1Cerebrovascular Disease Section, Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|September 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences of bioelectrical impedance in the development and healing phase of pressure ulcers and erythema in mouse model.

Journal of tissue viability·2024
Same author

Clinicopathological characteristics of myelodysplastic syndromes with del(5q) in Taiwan.

The Malaysian journal of pathology·2023
Same author

Effect of acupuncture on atrial fibrillation stratified by CHA2DS2-VASc score-a nationwide cohort investigation.

QJM : monthly journal of the Association of Physicians·2021
Same author

Intravenous tissue plasminogen activator for acute ischemic stroke in patients with renal dysfunction.

QJM : monthly journal of the Association of Physicians·2020
Same author

Non-alcoholic fatty liver disease increases the prevalence of maintenance haemodialysis in patients with chronic kidney disease.

Bratislavske lekarske listy·2020
Same author

Antiplatelet agents for the secondary prevention of ischaemic stroke in patients with or without renal dysfunction.

European journal of neurology·2019
Same journal

Efficacy of Cognitive Behavioral Therapy for Post-Stroke Fatigue: A Systematic Review and Meta-Analysis.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same journal

Admission Cognitive Function Independently Predicts Discharge Walking Function and Functional Independence After Stroke: A Multicenter Retrospective Cohort Study.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same journal

Association Between Race, Ethnicity, and Sex with Prehospital Identification and Outcomes of Patients with Stroke.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same journal

Direct Oral Anticoagulants versus Aspirin for Prevention of Overt and Covert Cerebral Infarction: A Meta-Analysis.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same journal

Efficacy of Pharyngeal Balloon Muscle Resistance Treatment in Post-Stroke Dysphagia: A Randomized Controlled Trial.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same journal

Detection of atrial fibrillation via adhesive single-lead ECG vs. Holter monitoring in embolic stroke of undetermined source: the AVANT-GARDE trial.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
See all related articles

Neuroprotective drug effectiveness varies by mechanism, with some treatments requiring short windows and others longer durations. Optimizing neuroprotection involves balancing treatment duration against risks and benefits over time.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Stroke Research

Background:

  • Neuroprotective agents are crucial for managing ischemic stroke.
  • The duration of neuroprotection effectiveness is drug-specific, influenced by the mechanism of action.
  • Early events like glutamate excitotoxicity and later processes like apoptosis dictate treatment timing.

Purpose of the Study:

  • To analyze the varying therapeutic time windows for different neuroprotective drugs.
  • To discuss the practical implications of these time windows for clinical trials and drug administration.
  • To highlight the importance of considering drug-specific pharmacokinetics and pharmacodynamics in neuroprotection strategies.

Main Methods:

  • Review of neuroprotective mechanisms in ischemic stroke.

Related Experiment Videos

  • Analysis of the temporal profile of key pathological events (glutamate excitotoxicity, reperfusion injury, apoptosis).
  • Consideration of pharmacokinetic factors, dose-response curves, and clinical trial challenges.

    • Main Results:

    • Glutamate antagonists have short efficacy windows (1-2 hours) due to early toxicity.
    • Neurotrophic factors may be effective for weeks.
    • Drugs targeting reperfusion injury or apoptosis (caspase inhibitors) require longer treatment durations (1-2 days).

    Conclusions:

    • Therapeutic time windows for neuroprotectants significantly impact their clinical utility and trial design.
    • Short time windows pose challenges for clinical trials and achieving adequate brain concentrations.
    • Balancing drug benefits against time-dependent risks and adverse events is critical for effective neuroprotection strategies.